Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) is a global biotechnology company focused on hereditary angioedema (HAE) and other rare diseases, and its news flow reflects this specialization. Company press releases frequently highlight regulatory milestones, clinical data, commercial performance, and strategic transactions related to its flagship product ORLADEYO® (berotralstat) and its broader rare disease pipeline.
Investors following BCRX news can expect regular updates on ORLADEYO, described as the first oral, once-daily plasma kallikrein inhibitor for prophylaxis to prevent HAE attacks. Recent announcements have covered U.S. Food and Drug Administration approval of an oral pellet formulation for pediatric patients aged 2 to <12 years, interim data from the APeX-P pediatric trial showing early and sustained reductions in attack rates, and presentations at major allergy and immunology congresses on the burden of HAE in children and caregivers.
BioCryst also issues news on its financial outlook and operating performance, including preliminary ORLADEYO net revenue, total revenue guidance that incorporates RAPIVAB® (peramivir injection), and non-GAAP operating expense expectations. These releases often explain how structural changes, such as the sale of the European ORLADEYO business, affect the company’s revenue mix and cost base.
Strategic and corporate developments are another major theme in BCRX news. The company has announced a definitive agreement to acquire Astria Therapeutics, Inc., with updates on regulatory clearances such as early termination of the Hart-Scott-Rodino waiting period and expected closing timelines. Additional news items include leadership changes, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and planned presentations at high-profile investor conferences.
For readers tracking BCRX, this news stream offers insight into BioCryst’s commercial execution in HAE, progress of its rare disease pipeline, evolving capital allocation, and key corporate events. Regularly reviewing these updates can help contextualize movements in BCRX stock and provide a clearer picture of the company’s strategic direction.
BioCryst Pharmaceuticals (Nasdaq: BCRX) has successfully completed a public offering of 22,044,447 shares of common stock, generating approximately $115 million in gross proceeds. This includes the full exercise of underwriters’ options for 3,333,334 shares and pre-funded warrants for up to 3,511,111 shares. The funds will be utilized for various purposes, including the development of berotralstat and BCX9930, regulatory activities, and general corporate needs.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced its participation in the Jefferies Virtual Healthcare Conference on June 4, 2020, at 10:30 a.m. ET. The event aims to showcase the company's innovations in treating rare diseases through novel, oral, small-molecule medicines. Noteworthy development programs include berotralstat for hereditary angioedema and BCX9930, an oral Factor D inhibitor. A live audio webcast of the presentation will be available on BioCryst's website for investors.
BioCryst Pharmaceuticals (BCRX) has priced an underwritten public offering of 18,711,113 shares at $4.50 per share, alongside pre-funded warrants for an additional 3,511,111 shares at $4.49 each. The total gross proceeds are expected to reach $100 million before expenses. The offering will close around June 1, 2020, pending customary conditions. Proceeds will support various corporate initiatives, including development of berotralstat and BCX9930, among others. J.P. Morgan and Piper Sandler are managing the offering.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced it will present new data on berotralstat (BCX7353), an oral therapy for hereditary angioedema (HAE), at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) digital congress from June 6-8. Key data include findings from the APeX-S and APeX-2 studies, showcasing berotralstat's long-term safety and significant reduction in HAE attacks. As regulatory approvals approach in the U.S., Japan, and EU, Dr. William Sheridan emphasized berotralstat's potential impact on HAE patients.
Summary not available.
BioCryst Pharmaceuticals (Nasdaq: BCRX) will present at the Bank of America 2020 Healthcare Conference on May 14, 2020 at 9:00 a.m. ET and at the 2020 RBC Capital Markets Global Healthcare Conference on May 20, 2020 at 3:40 p.m. ET. Both events will be conducted virtually.
Investors can access live webcasts and replays of these presentations on BioCryst's website. The company focuses on developing novel, oral treatments for rare diseases, including berotralstat for hereditary angioedema and BCX9930, an oral Factor D inhibitor.
BioCryst Pharmaceuticals (BCRX) announced the grant of inducement stock options totaling 525,000 shares to two newly-hired employees, including 500,000 shares to CFO Anthony Doyle. The options, granted on April 30, 2020, have an exercise price of $3.91, equal to the stock's closing price on the previous day. Mr. Doyle's options include a vesting schedule tied to his employment status, while the other employee's options vest over four years. These grants comply with NASDAQ Listing Rule 5635(c)(4), aimed at attracting talent to support BioCryst's ongoing development in rare diseases.